NMRA-511 demonstrated a clinically meaningful effect size in people with AD agitation.Alzheimer's Disease Agitation DataIn the Phase 1b study, NMRA-511 showed a favorable safety profile with no somnolence or sedation, and meaningful improvements in agitation. Patients saw placebo-adjusted CMAI total score changes of -2.6 and -2.1 at Weeks 6 and 8, while those with elevated anxiety improved by -7.6 and -5.6, respectively.William Blair projects peak U.S. sales of $1.8 billion for NMRA-511 and called the early ...

Core Viewpoint - Novo Nordisk is viewed as a speculative buy, with contrasting opinions from analysts regarding its future performance and stock potential [1][4]. Group 1: Analyst Ratings - Morgan Stanley has downgraded Novo Nordisk to underweight due to disappointing growth in key prescriptions in the U.S. [1] - HSBC Holdings has upgraded its rating to buy, citing the potential of the company's pipeline [1]. Group 2: Stock Performance - Novo Nordisk shares have experienced a nearly 50% decline, attributed to market disappointment over Wegovy's share loss in the weight loss market to Eli Lilly's Zepbound [1]. Group 3: Upcoming Events - The company is leading the race for FDA approval of an oral weight loss pill (oral Wegovy), with a decision expected this year [2]. - Novo Nordisk is conducting a phase 3 trial of its next-generation weight loss drug, CagriSema, against Eli Lilly's tirzepatide, with results expected by mid-January [2]. - Results from a phase 3 trial of semaglutide in Alzheimer's patients are anticipated in late 2025 or early 2026, aiming to slow cognitive decline [3]. Group 4: Investment Considerations - While there are no guarantees regarding the outcomes of these trials, the potential upside from the upcoming events should not be overlooked, especially if oral Wegovy receives FDA approval in 2025 [4].